important parameters in MPS VI patients. White et al., in the second original research paper, use the Pediatric Outcomes Data Collection Instrument (PODCI) to demonstrate improvement in musculoskeletal health in MPS II patients after 1 year of enzyme replacement therapy (recombinant human I2S). PODCI is a validated, functional measure of musculoskeletal health in children with disabilities. Alliston in her article "Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI(Maroteaux-Lamy syndrome)", explores the hypothesis that accrued partially degraded glycosaminoglycans (GAGs) may contribute to deregulation of signaling pathways that normally orchestrate skeletal development. McDonald et al. in "Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)" describe the use of the 6-MWT (minute walk test), 12-MWT and 3-MSC (minute stair climb) as measures of endurance to evaluate MPS patient response to specific enzyme replacement therapy. In "Radiologic and Neuroradiologic Findings in the Mucopolysaccharidoses", Lachman et al. discuss the skeletal X-ray and neuroimaging findings in MPS patients and the imaging techniques that can be used for diagnosing and monitoring abnormalities in the skeleton and central nervous system. Finally, Wilson and Brömme in their article "Potential Role of Cathepsin K in the Pathophysiology of Mucopolysaccharidoses" propose a second basic science mechanism involving the inhibition of osteoclast function through altered activity of cathepsin K by GAGs for the bone disease seen in these patients.
As this and the previous issue demonstrate, the identification and characterization of the responsible en- 
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